<DOC>
	<DOCNO>NCT00061633</DOCNO>
	<brief_summary>Serious infection cause resistant bacteria become medical problem throughout world . One way deal problem develop new drug control bacteria . This study measure well TD-6424 ( Telavancin ) control infections whether drug safely give patient .</brief_summary>
	<brief_title>Phase 2 Trial TD 6424 ( Telavancin ) Versus Standard Therapy Complicated Gram Positive Skin Skin Structure Infections ( Gram Positive cSSSI )</brief_title>
	<detailed_description />
	<mesh_term>Infection</mesh_term>
	<mesh_term>Communicable Diseases</mesh_term>
	<mesh_term>Wound Infection</mesh_term>
	<mesh_term>Cellulitis</mesh_term>
	<mesh_term>Gram-Positive Bacterial Infections</mesh_term>
	<mesh_term>Penicillins</mesh_term>
	<mesh_term>Vancomycin</mesh_term>
	<mesh_term>Telavancin</mesh_term>
	<criteria>Patients must diagnosis one follow complicate skin skin structure infection either suspect confirmed Gram positive organism major cause infection : major abscess require surgical incision drainage infect burn ( see exclusion criterion important qualification ) deep/extensive cellulitis infect ulcer ( see exclusion criterion important qualification ) wind infection Patients must expect require least 4 day intravenous antibiotic treatment Previous systemic antibacterial therapy ( exception aztreonam metronidazole ) &gt; 24 hour within 7 day prior first dose study medication unless pathogen resistant prior treatment patient treatment failure ( clinical improvement 3 day ) . Burns involve &gt; 20 % body surface area third degree/full thickness nature , diabetic foot ulcer , ischemic ulcers/wounds , necrotizing fasciitis , gas gangrene , mediastinitis .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2010</verification_date>
</DOC>